Please provide your email address to receive an email when new articles are posted on . Phase 3 clinical trial included 134 adults with full neuroaxis MRI and no new NMOSD symptoms. At 28 weeks, 15% ...

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain ...

Neuromyelitis optica spectrum disorder (NMOSD) is a condition that affects your eyes and spinal cord. It is an autoimmune disorder where the immune system attacks healthy cells in the nervous system, ...

-- Post hoc analysis of UPLIZNA Phase 2/3 trial shows all seven patients who had attacks while receiving rituximab were attack-free after switching to UPLIZNA -- UPLIZNA is the first and only ...

Please provide your email address to receive an email when new articles are posted on . The study included 213 individuals with neuromyelitis optica spectrum disorder, with a subgroup of 40 ...

This is the third indication for UPLIZNA, which was previously approved by the FDA for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum ...

UPLIZNA is currently approved for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and is under priority FDA review for the ...

Amgen (NASDAQ:AMGN) announced Wednesday that its FDA-approved therapy, Uplizna, reached its main goal in a Phase 3 registrational trial for patients with immunoglobulin G4-related disease (IgG4-RD), ...

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting -- ...

THOUSAND OAKS, Calif., Dec. 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of ...